A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies. - Wikidata - wikimedia - TriplyDB

A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies.

A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies.

http://www.wikidata.org/entity/Q35483665

about

Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to date Tetraspanins as therapeutic targets in hematological malignancy: a concise review Advances in Therapeutic Fc Engineering - Modulation of IgG-Associated Effector Functions and Serum Half-life AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity Effect of an anti-human Co-029/tspan8 mouse monoclonal antibody on tumor growth in a nude mouse model.The tetraspanin CD37 orchestrates the α(4)β(1) integrin-Akt signaling axis and supports long-lived plasma cell survival.Anti-CD37 antibodies for chronic lymphocytic leukemia.Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art.Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma.Tetraspanin CD37 protects against the development of B cell lymphoma Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.Development of a cell-based assay measuring the activation of FcγRIIa for the characterization of therapeutic monoclonal antibodies Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells.Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity.A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.Targeting tetraspanins in cancer.Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment.Emerging therapies for refractory chronic lymphocytic leukemia.New targets for antibody therapy of pediatric B cell lymphomas.Promising therapies for the treatment of chronic lymphocytic leukemia.Emerging immunological drugs for chronic lymphocytic leukemia.Emerging antibody-drug conjugates for treating lymphoid malignancies.The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models.Binding structures and energies of the human neonatal Fc receptor with human Fc and its mutants by molecular modeling and dynamics simulations.Editorial: Membrane domains as new drug targets.Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment.Generation and preclinical characterization of an antibody specific for SEMA4D.Tetraspanin CD37 contributes to the initiation of cellular immunity by promoting dendritic cell migration.Plant-expressed Fc-fusion protein tetravalent dengue vaccine with inherent adjuvant properties.Alga-Made Anti-Hepatitis B Antibody Binds to Human Fcγ Receptors.Investigational therapies targeting CD37 for the treatment of B-cell lymphoid malignancies.Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.Surrogate potency assays: Comparison of binding profiles complements dose response curves for unambiguous assessment of relative potencies.

P2860

Q24336378-9EF41630-B864-418A-B3D5-6D4CE38C240B Q26798062-4E4D383A-E901-4895-BBC2-C3D897CDD47E Q27002353-E2C5D2A9-F1EE-448A-8045-75860305766A Q28079016-25993CBB-AC2A-43BF-B26E-06FB52801ED0 Q30403563-6F1DA497-1F7A-497B-B63A-1261D45748BC Q33875604-792775FA-4E42-406B-86DB-1749444CC7CE Q34204325-EB9A902B-2B50-474F-8DDA-A04EFE4670A9 Q34211752-0D6B906B-E9E9-4030-A353-0433F866CE5E Q34311595-ED580B96-9C09-463C-AB93-4B72137A1AB5 Q34405641-41036D3F-16CE-4EC9-B586-1940D909758D Q34440110-6B848E3E-B0A1-44AA-957C-413FB8852395 Q34480345-AEF766F2-E001-4076-A86B-F640393CA4A9 Q34509755-B58AA048-A7CD-468A-8406-70AA94803CF5 Q34543066-05840911-57F1-4A56-B7CA-02BFB67B746F Q35154170-21AD7E20-1009-443A-843D-C1FF07EB12C8 Q36989586-8406A929-7663-4805-9A4D-12F3F16EA96E Q37129235-E6FB804E-1B5E-4716-82DB-7B2F15397798 Q37364355-ED89687B-2A85-4E13-A66D-D63ABFF8217C Q37524313-4094E01E-6FFF-4BD9-BA2B-6BB33629D0FF Q37609420-0BACF66A-7541-4CC6-814D-41072E7DB0E1 Q37672472-E1DD19C7-CF2A-4F09-86BC-30E18E70A537 Q38033584-4881790B-E4DA-4D8D-AB10-BE6C1E27E150 Q38068494-3E62352B-7BE5-40FB-9BAF-225A55D0E07B Q38110472-FFF8D72E-610C-4B11-A085-9D84DD7D5742 Q38207143-5A6959E7-D412-4BC0-A16B-19DA8B8643E1 Q38242984-4DE0EA28-4DBE-45BD-A68D-D483649A5A3B Q38366441-804A2E72-B826-488B-9F40-FE4F20E386CF Q38543771-3A835D4D-4A4D-45B3-AD24-7BDE1E10191D Q38632313-C2E9C04C-EC89-49E5-9AE7-4F6F36C6F4D2 Q38655388-4A3E3658-6A2E-4A9F-820B-B241CE89E30F Q39346415-77665493-0FD6-477E-8E43-A4198A38C043 Q41513306-27F85D26-BEFF-4051-9BC0-4CD0F71E9653 Q42355445-36F65E5F-70FD-48CB-A149-E9F810337B5C Q42393761-8A146F8B-FFA0-4804-8CFE-64317FD3CB64 Q44501041-7235E0DD-B83A-4C0A-A38C-EAF257332544 Q47265866-D6791353-6655-410E-A14F-496BFAB176DD Q47341896-ABC444AB-B0D7-4CC6-A474-AD29EC5965F5 Q48541938-1FECD50D-4F81-4695-A7F8-41ED53B41C03 Q49539698-0EEDF115-0B10-4D6C-BD67-7C87F7167CFA Q54988566-C78DE939-3DEE-467A-8F54-63A1DB486AF0

P2860

A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies.

http://www.wikidata.org/entity/Q35483665

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

A novel Fc-engineered monoclon ...... atment of B-cell malignancies.

@ast

A novel Fc-engineered monoclon ...... atment of B-cell malignancies.

@en

type

label

A novel Fc-engineered monoclon ...... atment of B-cell malignancies.

@ast

A novel Fc-engineered monoclon ...... atment of B-cell malignancies.

@en

prefLabel

A novel Fc-engineered monoclon ...... atment of B-cell malignancies.

@ast

A novel Fc-engineered monoclon ...... atment of B-cell malignancies.

@en

P1433

Q35483665-469E8894-4CB1-4F07-9EBD-B480A85276E2

P1476

Q35483665-FC9D936B-D773-4549-AC82-14420306AE48

P2093

Q35483665-08EBABB1-8F74-4DAB-941E-127AEDAA8445

Q35483665-0B431EEE-AA61-49A4-AFB3-675ABAF734BE

Q35483665-0C4A1038-1810-41DD-8138-C29D51B74B39

Q35483665-86D97051-8CCE-4D58-B883-D9A0654842F5

Q35483665-8C3D4F98-8EDE-409C-9F11-B4BE71776000

Q35483665-924B92D1-4E92-4B0D-B5F0-4F66BD34529E

Q35483665-A5DDF3EB-C4FF-41DA-B4E0-E8F15327E98A

Q35483665-A7551829-9267-4078-B793-E1F1E04F6DBD

Q35483665-AF5BAD3F-D6D7-496B-97EC-7675AEE38FCC

Q35483665-E1468738-0F94-4070-B492-3AC9928839DE

P2860

Q35483665-023E21BD-540F-41D5-AF4D-C60AFC615F71

Q35483665-06654CBC-B28E-4E42-BCC4-1A2FE860AFAD

Q35483665-072C238C-9355-4DA5-B4C9-E7A9B90ED545

Q35483665-19CBD6DC-5A5B-4FEA-995F-26830049C2C4

Q35483665-21A31650-F38D-4186-8B89-EE7238C96899

Q35483665-249F9337-2748-42F8-BC56-9083E7A7B788

Q35483665-2F294EAA-B339-406F-A611-E99B0359B91A

Q35483665-300D702F-F628-42E7-9820-380A60641442

Q35483665-4AC032D0-882C-4D91-B9FC-93804B727E4A

Q35483665-5B3A0A94-E4E3-49A5-BCAC-0838E81B853D

P304

Q35483665-EF5F22BF-0C23-4964-875A-36B26E104EA9

P31

Q35483665-ABD8764A-11CF-4421-8F64-4DD23637F916

P356

Q35483665-9622F1F0-4CC2-4CFE-A910-23A8E32E22E5

P407

Q35483665-9291572C-FE9A-49F1-957E-FAC74EE0FF93

P433

Q35483665-11A503EA-339E-432A-9779-35C74D8D777B

P478

Q35483665-309A6151-DDF3-46BC-8A3B-C987B2BA38C0

P50

Q35483665-68B210D7-2B88-4F1A-BB49-8B383890C529

Q35483665-6FAE8524-E582-4BAE-A9B4-428A268AA30E

P577

Q35483665-23107404-E542-4180-A295-0FA192F46156

P5875

Q35483665-8A5B0245-AEC8-4251-8516-9FFB714CAEA1

P698

Q35483665-9BB466FF-B181-4FD7-BBF8-A1FE92C41B72

P921

Q35483665-9093AD0F-E580-4D14-8643-1E4C03FAB14D

P932

Q35483665-E1FC7F87-7333-4369-9592-E481997FF70A

P356

BLOOD-2011-04-351932

P1433

P1476

A novel Fc-engineered monoclon ...... atment of B-cell malignancies.

@en

P2093

Alexander Jacobi

http://www.w3.org/2001/XMLSchema#string

Anke Baum

http://www.w3.org/2001/XMLSchema#string

Elinborg Ostermann

http://www.w3.org/2001/XMLSchema#string

Eric Borges

http://www.w3.org/2001/XMLSchema#string

Günther R Adolf

http://www.w3.org/2001/XMLSchema#string

Herbert Lamche

http://www.w3.org/2001/XMLSchema#string

Karl-Heinz Heider

http://www.w3.org/2001/XMLSchema#string

Kerstin Kiefer

http://www.w3.org/2001/XMLSchema#string

Matthias Volden

http://www.w3.org/2001/XMLSchema#string

Steffen Müller

http://www.w3.org/2001/XMLSchema#string

P2860

Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical

A regulatory role for CD37 in T cell proliferation

The B cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.

Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma.

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.

Engineered antibody Fc variants with enhanced effector function.

P304

4159-4168

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-04-351932

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

Stephan Stilgenbauer

P577

2011-07-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51527294

http://www.w3.org/2001/XMLSchema#string

P698

21795744

http://www.w3.org/2001/XMLSchema#string

P921

P932

3204733

http://www.w3.org/2001/XMLSchema#string